[Pharmacogenetics and age-related macular degeneration, towards an individualized treatment of the disease]

Arch Soc Esp Oftalmol. 2013 Oct;88(10):371-2. doi: 10.1016/j.oftal.2013.03.006. Epub 2013 May 15.

[Article in Spanish]

Authors

F Cruz-González¹, L Cabrillo Estévez, G López-Valverde, F Escudero-Domínguez, R González-Sarmiento

Affiliation

¹ Servicio de Oftalmología, Hospital Universitario de Salamanca, Salamanca, España; Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca, Salamanca, España. Electronic address: cruzgonzalez.fernando@gmail.com.

PMID: 24060299
DOI: 10.1016/j.oftal.2013.03.006

No abstract available

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / pharmacokinetics
Angiogenesis Inhibitors / therapeutic use*
Complement C3b / genetics
Complement Factor H / genetics*
Diseases in Twins
Drug Resistance / genetics
Genetic Association Studies
Genetic Heterogeneity
Genetic Predisposition to Disease
Genetic Variation
High-Temperature Requirement A Serine Peptidase 1
Humans
Macular Degeneration / drug therapy*
Macular Degeneration / genetics
Polymorphism, Single Nucleotide
Precision Medicine*
Proteins / genetics
Serine Endopeptidases / genetics
Treatment Outcome
Vascular Endothelial Growth Factor A / genetics*

Substances

ARMS2 protein, human
Angiogenesis Inhibitors
Proteins
VEGFA protein, human
Vascular Endothelial Growth Factor A
Complement C3b
Complement Factor H
High-Temperature Requirement A Serine Peptidase 1
HTRA1 protein, human
Serine Endopeptidases